SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: Persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors.
Antibodies
COVID-19
Immunity
Neutralizing
SARS-CoV-2
Spike
Journal
European journal of internal medicine
ISSN: 1879-0828
Titre abrégé: Eur J Intern Med
Pays: Netherlands
ID NLM: 9003220
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
21
03
2021
revised:
29
04
2021
accepted:
07
05
2021
pubmed:
1
6
2021
medline:
8
7
2021
entrez:
31
5
2021
Statut:
ppublish
Résumé
Elucidating the characteristics of human immune response against SARS-CoV-2 is of high priority and relevant for determining vaccine strategies. We report the results of a follow-up evaluation of anti-SARS-CoV-2 antibodies in 148 convalescent plasma donors who participated in a phase 2 study at a median of 8.3 months (range 6.8-10.5 months) post first symptom onset. Monitoring responses over time, we found contraction of antibody responses for all four antigens tested, with Spike antibodies showing higher persistence than Nucleocapsid antibodies. A piecewise linear random-effects multivariate regression analysis showed a bi-phasic antibody decay with a more pronounced decrease during the first 6 months post symptoms onset by analysis of two intervals. Interestingly, antibodies to Spike showed better longevity whereas their neutralization ability contracted faster. As a result, neutralizing antibodies were detected in only 76% of patients at the last time point. In a multivariate analysis, older age and hospitalization were independently associated with higher Spike, Spike-RBD, Nucleocapsid, N-RBD antibodies and neutralizing antibody levels. Results on persistence and neutralizing ability of anti-SARS-CoV-2 antibodies, especially against Spike and Spike-RBD, should be considered in the design of future vaccination strategies.
Identifiants
pubmed: 34053848
pii: S0953-6205(21)00161-8
doi: 10.1016/j.ejim.2021.05.010
pmc: PMC8128693
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Spike Glycoprotein, Coronavirus
0
Types de publication
Clinical Trial, Phase II
Journal Article
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
87-96Informations de copyright
Copyright © 2021 European Federation of Internal Medicine. All rights reserved.
Références
Clin Exp Med. 2021 May;21(2):167-179
pubmed: 33128197
Blood. 2020 Nov 26;136(22):2588-2591
pubmed: 33001206
N Engl J Med. 2020 Oct 22;383(17):1695
pubmed: 32966711
mSphere. 2021 Aug 25;6(4):e0027521
pubmed: 34431693
Genome Med. 2018 Jul 27;10(1):59
pubmed: 30053915
N Engl J Med. 2020 Oct 22;383(17):1697-1698
pubmed: 32966713
Eur J Immunol. 2020 Dec;50(12):2025-2040
pubmed: 33084029
Sci Immunol. 2020 Dec 22;5(54):
pubmed: 33443036
Am J Trop Med Hyg. 2020 Dec;103(6):2412-2418
pubmed: 33124544
Wien Klin Wochenschr. 2021 Sep;133(17-18):931-941
pubmed: 34378087
N Engl J Med. 2020 Sep 10;383(11):1085-1087
pubmed: 32706954
J Infect. 2021 Apr;82(4):84-123
pubmed: 33207255
Med (N Y). 2021 Mar 12;2(3):281-295.e4
pubmed: 33589885
Clin Infect Dis. 2020 Nov 19;71(16):2255-2258
pubmed: 32337590
J Clin Virol. 2020 Sep;130:104542
pubmed: 32707511
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
Front Microbiol. 2020 Oct 19;11:584251
pubmed: 33193227
Lancet Infect Dis. 2021 Jan;21(1):52-58
pubmed: 33058797
J Infect Dis. 2021 Feb 13;223(3):389-398
pubmed: 33140086
N Engl J Med. 2020 Oct 29;383(18):1724-1734
pubmed: 32871063
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Emerg Infect Dis. 2016 Oct;22(10):1824-6
pubmed: 27332149
Euro Surveill. 2020 Nov;25(45):
pubmed: 33183404
J Infect. 2021 May;82(5):186-230
pubmed: 33271171
J Microbiol Immunol Infect. 2020 Oct;53(5):821-822
pubmed: 32249185
N Engl J Med. 2020 Oct 22;383(17):1695-1696
pubmed: 32966712
JAMA Intern Med. 2020 Oct 1;180(10):1356-1362
pubmed: 32808970
Sci Immunol. 2020 Dec 7;5(54):
pubmed: 33288645
JAMA Intern Med. 2021 Apr 1;181(4):450-460
pubmed: 33231628
Front Med. 2020 Dec;14(6):746-751
pubmed: 33017040
Hemasphere. 2020 May 21;4(3):e409
pubmed: 32647807
N Engl J Med. 2007 Sep 13;357(11):1162-3
pubmed: 17855683
Lancet. 2021 Apr 17;397(10283):1459-1469
pubmed: 33844963
mBio. 2020 Oct 16;11(5):
pubmed: 33067385
Microorganisms. 2020 Nov 28;8(12):
pubmed: 33260775
J Virol. 2021 Jan 13;95(3):
pubmed: 33144321
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
Science. 2020 Dec 4;370(6521):1227-1230
pubmed: 33115920
J Infect Dis. 2021 Sep 17;224(6):983-988
pubmed: 33693749
Life (Basel). 2020 Sep 21;10(9):
pubmed: 32967110
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
N Engl J Med. 2020 Dec 17;383(25):2427-2438
pubmed: 32991794
Signal Transduct Target Ther. 2020 Sep 2;5(1):180
pubmed: 32879307
J Infect Dis. 2021 Feb 24;223(4):589-599
pubmed: 33247924
N Engl J Med. 2020 Oct 22;383(17):1694-1695
pubmed: 32966710
Clin Infect Dis. 2020 Dec 17;71(10):2688-2694
pubmed: 32497196
J Clin Invest. 2020 Nov 2;130(11):6141-6150
pubmed: 32764200
Cell. 2021 Mar 4;184(5):1201-1213.e14
pubmed: 33571429
Nat Commun. 2020 Sep 17;11(1):4704
pubmed: 32943637
J Infect Dis. 2021 Feb 3;223(2):197-205
pubmed: 33535236
N Engl J Med. 2021 Jan 7;384(1):80-82
pubmed: 33270381
Nat Commun. 2020 Nov 27;11(1):6044
pubmed: 33247152
Viruses. 2020 Dec 04;12(12):
pubmed: 33291713